The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. SLEEP 2026 blazes into Baltimore This year’s SLEEP a...

The American Academy of Sleep Medicine installs its new board of directors president to lead advocacy and clinical practice initiatives for its 9,500 members.

The National Sleep Foundation conducts a 10-year review of 133 meta-analyses for insights into whether the science has evolved.

The expanded reimbursement access aims to make the FDA-cleared device more affordable for patients with conditions linked to hypoxia.

The American Academy of Sleep Medicine recently recognized nine sleep centers for maintaining AASM accreditation for 40 continuous years, reflecting their long-standing dedication to providing high-quality care for peopl...

On April 14, 2026, the Centers for Medicare & Medicaid Services (CMS) published the Interoperability Standards and Prior Authorization for Drugs Proposed Rule, representing a significant step toward modernizing prior...

New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.

The integration allows clinicians to manage Onera studies directly within the Somnoware sleep lab management platform.

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

The collaboration integrates data from the ProSomnus RPMO₂ into MonitAir’s platform to support longitudinal tracking.